Table 1.
Association analysis of NRIP3 upregulation in tumors with clinicopathologic characteristics of ESCC patients.
| Clinicopathologic characteristics | Total | NRIP3 upregulation | P value |
|---|---|---|---|
| Sex | 0.768 | ||
| Female | 113 | 74 (65.5%) | |
| Male | 160 | 102 (63.8%) | |
| Age | 0.948 | ||
| <60 | 140 | 90 (64.3%) | |
| ⩾60 | 133 | 86 (64.7%) | |
| Differentiation | 0.834 | ||
| Well | 70 | 47 (67.1%) | |
| Moderate | 134 | 86 (64.2%) | |
| Poor | 69 | 43 (62.3%) | |
| Tumor invasion | 0.003 | ||
| 0–1 | 82 | 41 (50.0%) | |
| 2 | 69 | 46 (66.7%) | |
| 3 | 122 | 89 (73.0%) | |
| LN metastasis | <0.001 | ||
| − | 203 | 116 (57.1%) | |
| + | 70 | 60 (85.7%) | |
| TNM stage | <0.001 | ||
| Early (0 + I) | 78 | 41 (52.6%) | |
| Moderate (II + III) | 150 | 94 (62.7%) | |
| Advanced (IV) | 45 | 41 (91.1%) |
Bold values indicates statistical significance.